Cedars-Sinai's IBD Drug Discovery and Development Unit (IBD3) has an extensive biorepository containing a large number of clinical samples, accessible for research and biomarker development.

A table showing the number and types of samples is shown below. 

*Samples are continually collected and added to the biorepository.

Android app on Google Play